Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 3
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the saf…
Hereditary Angioedema (HAE)Hereditary Angioedema - Type 1Hereditary Angioedema - Type 2+1 more
Estimated
~$10 – $8,750
ADARx Pharmaceuticals, Inc.NCT07428499
Phase 3
An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less Than 12 Years Old With Hereditary Angioedema
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HA…
Hereditary Angioedema (HAE)
Estimated
~$10 – $8,750
Ionis Pharmaceuticals, Inc.NCT07298447
Phase 3
A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-releas…
Hereditary Angioedema (HAE)
Estimated
~$10 – $7,500
Pharvaris Netherlands B.V.NCT06679881
Phase 1
Oral Deucrictibant for the Prophylactic and Acute Treatment in Patients With Bradykinin Mediated Angioedema With Normal C1 Inhibitor (BK-AE-nC1INH)
To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also a…
Hereditary Angioedema (HAE)AngioedemaBradykinin-mediated Angioedema+1 more
Estimated
~$10 – $7,500
Institute for Asthma and AllergyNCT07046806